New trial aims to match sepsis treatments to Patients' unique traits
NCT ID NCT06381661
First seen Jan 29, 2026 · Last updated Jun 20, 2026 · Updated 19 times
Summary
This study tests whether giving sepsis patients drugs tailored to their specific biological traits can improve survival and reduce the need for life support. It will enroll 2000 adults and children across multiple countries, using an adaptive platform to test several treatments at once. The goal is to move away from one-size-fits-all sepsis care toward more personalized medicine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tocilizumab, Baricitinib, Anakinra, Hydrocortisone
What this could lead to
If successful, this could show that matching sepsis treatments to individual patient traits improves survival and reduces time on life support.
What could go wrong
This is an early Phase 2 exploratory trial, so results may not confirm effectiveness. The complex adaptive design may also make it harder to draw clear conclusions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.